Cargando…

Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis

BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchand, Mathilde, Brossard, Patrick, Merdjan, Henri, Lama, Nicola, Weitkunat, Rolf, Lüdicke, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681983/
https://www.ncbi.nlm.nih.gov/pubmed/28283988
http://dx.doi.org/10.1007/s13318-017-0405-2
_version_ 1783278016806256640
author Marchand, Mathilde
Brossard, Patrick
Merdjan, Henri
Lama, Nicola
Weitkunat, Rolf
Lüdicke, Frank
author_facet Marchand, Mathilde
Brossard, Patrick
Merdjan, Henri
Lama, Nicola
Weitkunat, Rolf
Lüdicke, Frank
author_sort Marchand, Mathilde
collection PubMed
description BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix(®) NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21–66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13318-017-0405-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5681983
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-56819832017-11-22 Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis Marchand, Mathilde Brossard, Patrick Merdjan, Henri Lama, Nicola Weitkunat, Rolf Lüdicke, Frank Eur J Drug Metab Pharmacokinet Original Research Article BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix(®) NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21–66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13318-017-0405-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-03-10 2017 /pmc/articles/PMC5681983/ /pubmed/28283988 http://dx.doi.org/10.1007/s13318-017-0405-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Marchand, Mathilde
Brossard, Patrick
Merdjan, Henri
Lama, Nicola
Weitkunat, Rolf
Lüdicke, Frank
Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title_full Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title_fullStr Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title_full_unstemmed Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title_short Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
title_sort nicotine population pharmacokinetics in healthy adult smokers: a retrospective analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681983/
https://www.ncbi.nlm.nih.gov/pubmed/28283988
http://dx.doi.org/10.1007/s13318-017-0405-2
work_keys_str_mv AT marchandmathilde nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis
AT brossardpatrick nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis
AT merdjanhenri nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis
AT lamanicola nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis
AT weitkunatrolf nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis
AT ludickefrank nicotinepopulationpharmacokineticsinhealthyadultsmokersaretrospectiveanalysis